As the market leader of follicular unit extraction devices in the United States of America, this move furthers NeoGraft's® mission to become the most trusted global authority on minimally invasive hair restoration.
"Medicamat® has been a dedicated partner for almost a decade and their reputation is respected across the globe," said Glenn Normoyle, President of NeoGraft. "Acquiring Medicamat® stabilizes our core offering, while accelerating our research and development pipeline."
The acquisition brings all of Medicamat's® assets under NeoGraft® Solutions' brand umbrella, and follows a series of moves by NeoGraft® to distinguish itself as more than a traditional medical device company.
"Acquiring Medicamat® deepens NeoGraft's commitment to patient safety and physician education programs. As we continue to broaden our offering away from a single device, we now provide a complete continuum of care for hair restoration, both surgically and non-surgically.
“We are dedicated to making sure our patients have the best options and make the most informed choices for treating their hair loss," said Jack Fisher, MD, NeoGraft Chief Medical Officer, Board Certified Plastic Surgeon, and former President of The American Society for Aesthetic Plastic Surgery.
NeoGraft® is the first FDA-cleared follicular unit harvesting and implantation system that extracts individual hair follicles.
Compared to the traditional strip method, a NeoGraft® procedure is minimally invasive, requires significantly less recovery time, and has 20 years of clinically proven results. NeoGraft® Solution's vision is to be the world leader in hair restoration, supplying the latest innovations in technology, education, and patient care.
